Professional
Added to YB: 2026-10-14
Pitch date: 2026-09-28
LOVE.TO [bullish]
Cannara Biotech Inc.
-6.42%
current return
Author Info
Atrium Research provides institutional quality research on underfollowed public equities. Sign up for the newsletter.
Company Info
Cannara Biotech Inc., together with its subsidiaries, engages in the indoor cultivation, processing, and sale of cannabis and cannabis-derivative products in Canada.
Market Cap
CAD 205.3M
Pitch Price
CAD 2.18
Price Target
3.00 (+47%)
Dividend
N/A
EV/EBITDA
8.82
P/E
18.92
EV/Sales
1.88
Sector
Personal Care Products
Category
growth
Cannara Biotech – Q4 Preview and Hifyre Data Review; Staying Bullish
LOVE.TO (hold): Cannara’s Hifyre-tracked share outside Quebec rose from 2.5% in January to 2.8% in August, while low penetration of large formats leaves runway as grow rooms activate and products launch. Q4 revenue and adjusted EBITDA are forecast to rise 17% and 11% year over year, respectively, despite slight margin compression. The $3.00 target is maintained; discounted valuation and Canopy’s MTL Cannabis acquisition at 11.6x LTM EBITDA underscore re-rating potential.
Read full article (6 min)